Free Trial

Amylyx Pharmaceuticals (AMLX) Stock Forecast & Price Target

$2.02
+0.02 (+1.00%)
(As of 07/19/2024 ET)

Amylyx Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 8 Wall Street analysts who have issued ratings for Amylyx Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Hold." Out of the 8 analysts, 6 have given a hold rating, and 2 have given a buy rating for AMLX.

Consensus Price Target

$17.60
771.29% Upside
High Forecast$37.00
Average Forecast$17.60
Low Forecast$3.00

According to the 8 analysts' twelve-month price targets for Amylyx Pharmaceuticals, the average price target is $17.60. The highest price target for AMLX is $37.00, while the lowest price target for AMLX is $3.00. The average price target represents a forecasted upside of 771.29% from the current price of $2.02.

TypeCurrent Forecast
7/21/23 to 7/20/24
1 Month Ago
6/21/23 to 6/20/24
3 Months Ago
4/22/23 to 4/21/24
1 Year Ago
7/21/22 to 7/21/23
Consensus Rating
Hold
Hold
Hold
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
5 Buy rating(s)
Hold
6 Hold rating(s)
6 Hold rating(s)
6 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$17.60$28.67$32.67$49.17
Forecasted Upside771.29% Upside198.51% Upside165.85% Upside56.62% Upside
Get Amylyx Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for AMLX and its competitors with MarketBeat's FREE daily newsletter.

AMLX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

AMLX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Amylyx Pharmaceuticals Stock vs. The Competition

TypeAmylyx PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.25
2.72
2.51
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside771.29% Upside1,426.46% Upside10.02% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/12/2024The Goldman Sachs Group
2 of 5 stars
 Boost TargetNeutral ➝ Neutral$3.00 ➝ $4.00+75.44%
7/10/2024HC Wainwright
3 of 5 stars
 Reiterated RatingBuy ➝ Buy$8.00 ➝ $8.00+306.09%
5/14/2024Mizuho
2 of 5 stars
 Lower TargetNeutral ➝ Neutral$4.00 ➝ $3.00+64.83%
3/11/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Goodman
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
3/11/2024SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform
3/11/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Neutral
3/8/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ In-Line
12/12/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$36.00+152.63%
6/26/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$53.00 ➝ $48.00+108.15%
1/5/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$50.00+40.69%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 07:54 AM ET.

AMLX Forecast - Frequently Asked Questions

What is Amylyx Pharmaceuticals' forecast for 2024?

According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for Amylyx Pharmaceuticals is $17.60, with a high forecast of $37.00 and a low forecast of $3.00.

Should I buy or sell Amylyx Pharmaceuticals stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amylyx Pharmaceuticals in the last year. There are currently 6 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AMLX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMLX, but not buy additional shares or sell existing shares.

Does Amylyx Pharmaceuticals's stock price have much upside?

According to analysts, Amylyx Pharmaceuticals's stock has a predicted upside of 184.84% based on their 12-month stock forecasts.

What analysts cover Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals has been rated by research analysts at HC Wainwright, Mizuho, and The Goldman Sachs Group in the past 90 days.

Do Wall Street analysts like Amylyx Pharmaceuticals more than its competitors?

Analysts like Amylyx Pharmaceuticals less than other "medical" companies. The consensus rating for Amylyx Pharmaceuticals is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how AMLX compares to other companies.


This page (NASDAQ:AMLX) was last updated on 7/20/2024 by MarketBeat.com Staff

From Our Partners